Stenocare bases itself on Danish pharmaceutical traditions
Driven by a desire to bring relief to chronic and terminally ill patients, Stenocare is building on true Danish pharmaceutical traditions to provide controlled substances to the world. Following a series of regulatory approvals that allow the company to supply medical cannabis oil products, Stenocare is expanding in the growing medical cannabis market and now serves Scandinavian and UK markets with government-controlled cannabis oil products.
Stenocare is a Danish company that cultivates, produces, imports and sells prescription-based medical cannabis
Stenocare is a Danish pharmaceutical company founded in 2017. The following year, Stenocare became the first Danish company to obtain all permits to cultivate, import and trade in medicinal cannabis oils in a Danish pilot scheme. Stenocare is also the only Danish company that has succeeded in having medical oil-based cannabis products approved for the Danish pilot scheme, and currently supply pharmaceutically-produced and uniform oil products to Danish, Swedish and UK patients.
The pharmaceutical approach ensured crucial permits
Scientific controllability, transparent processes and uniformity of products are essential to the credibility of a pharmaceutical company and to gain the trust of physicians and the many possible patients on the market. Optimising every detail and controlling the trust and quality of any product is a working method that CEO Thomas Skovlund Schnegelsberg recognises from his many years in the IT industry and now actively uses at Stenocare.
“I went from an industry that is 100 percent digital and technology-based to one that is based on nature’s processes. Stenocare stive to have 100 percent control over the digital ecosystem, risk management and optimisation of processes and product quality. Even though the plant is basically a natural product, it was crucial to create a framework for its development that can be quality assured, controlled and optimised and thereby accepted and approved as prescription drugs,” says CEO Thomas Skovlund Schnegelsberg, emphasising that the technological and detail-driven cultivation process for cannabis plants is based solely on indoor climate-controlled cultivation rooms – which makes Stenocare a pharmaceutical company as opposed to cultivation in greenhouses which are significantly more difficult to control.
Our high pharmaceutical standard has led to success in several markets, and the team behind Stenocare has succeeded in obtaining approvals in several important markets.
Stenocare has partnered with leading producers of medical cannabis with the aim of importing their finished products into Denmark, Sweden and the UK. Stenocare wants to partner with several suppliers to achieve better security of supply and offer patients a broader range of products for their treatment based on medical cannabis.
Stenocare’s core ambition is to provide more patients with a reliable, well-documented and easily accessible pharmaceutical alternative of the highest quality for the many patients who are seeking good clinical outcomes without being criminalised via illegal markets or losing their basic rights.
Stenocare founders want to improve the quality of life of patients and reduce the feeling of powerlessness of their loved ones
Like many other Danes, the founders of Stenocare themselves have witnessed family members losing sleep, appetite and peace of mind in the course of serious illnesses. This problem is a highly motivating factor for our management team every day, and for the three founders of Stenocare.
“Improving the quality of life for patients in very difficult moments of life and giving them more tolerable days during the course of their illness is what drives us all at Stenocare and keeps us striving to obtain approvals for the distribution and prescription of medical cannabis in more and more markets. For the ill and their relatives, we do not want to ever have to go through such a powerless course of illness, as all three of us have witnessed such pain up close,” says CEO Thomas Skovlund Schnegelsberg.
Backed by a management team with broad competencies and with his many years of management and organizational experience, CEO Thomas Skovlund Schnegelsberg has entered a completely new industry with the goal of creating a more bearable and dignified course of illness and treatment for patients.
Stenocare’s goal is to become the leading European brand in prescription-based medical cannabis products which are manufactured according to pharmaceutical principles of Good Manufacturing Practice (GMP).
Cannabis plants grow without soil and under artificial sunlight to ensure high quality and uniformity
“Generally speaking, our plants live a completely isolated life without the same sun, air, rain and freedom that we humans enjoy. We supply pharmaceutical medicines, so we have to be able to completely control climate conditions and eliminate potential sources of contamination. That is why we at Stenocare have invested more than DKK 35 million in indoor production facilities,” says CEO Thomas Skovlund Schnegelsberg.
State-of-the-art production in Randers and an operating company north of Copenhagen
The cultivation facility at Randers is strategically focused on meeting pharmaceutical standards, and Stenocare has now built an experience-intensive organization that has effectively executed the strategies to achieve the crucial regulatory permits.
With a stable track record of obtaining approvals to sell cannabis products, Stenocare has built a solid strategy and a unique ability to execute with quality in a demanding market.
“Producers of medical cannabis can only enter new markets as a result of a long-term and targeted strategy based on trustworthiness, good communication with authorities and a common focus on controlling all the details of the value- and production chain. We have used the necessary resources to acquire both unique market knowledge and an efficient supplier and distribution network. It is our know-how that puts us at the forefront of the field and means that we have been able to deliver in countries where no one else has succeeded,” says CEO Thomas Skovlund Schnegelsberg